PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known		
				Application Number	10/594,443	
				Filing Date	December 20, 2006	
				First Named Inventor	KOTANI	
				Group Art Unit	1648	
(use as many sheets as necessary)				Examiner Name	Stacy Brown Chen	
Sheet	1	of	1	Attorney Docket Number	007123.00001	

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			

	FOREIGN PA	TENT DOCU	MENTS		
Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (<i>if known</i>)	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	T ⁶
		IVIIII DO TTTT		Figures Appear	
	OTHER PRIOR ART NON P	ATENT LITE	RATURE DOCUM	ENTS	
Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
FUJIHARA <i>et al.</i> , "Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation," <i>Cancer Immunol. Immunother.</i> 57, 73-84, 2008 KAWAGUCHI <i>et al.</i> , "Efficient eradication of hormone-resistant human prostate cancers by inactivated Sendai virus particle," <i>Int. J. Cancer</i> 124, 2478-87, 2009					
	KUROOKA & KANEDA, "Inactivated Sendai Virus Particles Eradicate Tumors by Inducing Immune Responses through Blocking Regulatory T Cells," <i>Cancer Res</i> 67, 227-236, 2007				
	No.1	Cite No.¹ Country Code³ - Number⁴ - Kind Code⁵ (if known) OTHER PRIOR ART NON F Include name of the author (in CAPIT the item (book, magazine, journal, se number(s), publish FUJIHARA et al., "Intratumoral ir strong antitumor activity by enhan activation," Cancer Immunol. Imm KAWAGUCHI et al., "Efficient et cancers by inactivated Sendai virus KUROOKA & KANEDA, "Inactir Inducing Immune Responses throu	Cite No.1 OTHER PRIOR ART NON PATENT LITE Cite No.1 Include name of the author (in CAPITAL LETTERS), the item (book, magazine, journal, serial, symposium number(s), publisher, city and/or FUJIHARA et al., "Intratumoral injection of ina strong antitumor activity by enhancing local CX activation," Cancer Immunol. Immunother. 57, "KAWAGUCHI et al., "Efficient eradication of I cancers by inactivated Sendai virus particle," In KUROOKA & KANEDA, "Inactivated Sendai Inducing Immune Responses through Blocking	Cite No.1 OTHER PRIOR ART NON PATENT LITERATURE DOCUM Include name of the author (in CAPITAL LETTERS), title of the article (where the item (book, magazine, journal, serial, symposium, catalog, etc.), date, number(s), publisher, city and/or country where publish FUJIHARA et al., "Intratumoral injection of inactivated Sendai virus strong antitumor activity by enhancing local CXCL10 expression a activation," Cancer Immunol. Immunother. 57, 73-84, 2008 KAWAGUCHI et al., "Efficient eradication of hormone-resistant I cancers by inactivated Sendai virus particle," Int. J. Cancer 124, 24 KUROOKA & KANEDA, "Inactivated Sendai Virus Particles Era Inducing Immune Responses through Blocking Regulatory T Cells	Cite No.1 OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS Cite No.1 Cite Other Agpleadary Cited on Patentic of Cited Paperary Paperary Cite No.1 Cite Other Agpleadary Cite No.1 Cite No.1

Examiner Signature	Date Considered	